All News
Disease Modification, Disparities and the Next Therapeutic Frontier in Gout
Gout management has entered what Dr. Robert Terkeltaub MD from UC San Diego described as its “disease-modifying era,” during his talk at RheumNow Live 2026. In a recent comprehensive review of the past, present, and future of gout therapy, the central message was clear: “We can really apply disease modification to gout based on prospective, randomized controlled trials.”
Read Article
Maui Potpourri (2.13.2026)
Dr. Jack Cush reviews the hot item takeaways from last week's RheumNow.Live 2026.
Read Article
Obesity, Surgery, and Optimizing Patient Care
Rheumatologic care requires a multidisciplinary approach and collaboration with other specialties to treat complex systemic diseases. While many Pods at RheumNow Live are disease-specific, the Pod II focused on Advancing Practice on https://t.co/hvSY5yHZmd
Dr. John Cush RheumNow ( View Tweet)
The vasculitis session at #RNL26 was a fantastic update on inflamed blood vessels, large and small, by two experts in the field.
https://t.co/KuVei8jiFu https://t.co/PR4h2qniEL
Links:
Dr. John Cush RheumNow ( View Tweet)
RT @gibson_rheumPAC
Helicobacter pylori Update: H. Pylori remains the most common chronic bacterial infection worldwide, acquired in childhood and lifelong if untreated. Its clinical impact spans far beyond dyspepsia—from ulcers to malignancy. #RNL26 tis
Dr. John Cush RheumNow ( View Tweet)
“The ultimate measure of a man is not where he stands in moments of comfort and convenience, but where he stands at times of challenge and controversy.”
- Martin Luther King, Jr.
Dr. John Cush RheumNow ( View Tweet)
RT @gibson_RheumPAC
Axial PsA remains an area of active investigation. IL-17 inhibitors show consistent benefit, while IL-23 data are emerging—highlighting nuances when axial symptoms drive treatment choice. #RNL26 https://t.co/XFL3Sf8iK4
Dr. John Cush RheumNow ( View Tweet)
RT @Gibson_RheumPAC
A good reminder: PsA treatment should be domain-based. Skin, peripheral joints, axial disease, and enthesitis may each favor different pathways. #RNL26 https://t.co/IUCsdlNopo
Dr. John Cush RheumNow ( View Tweet)
RT @ericdeinMD
#RNL26
GLP on Knee OA
STEP 9 Trial - 68 wk
Mean WOMAC improved by 41.7 pts, compared to 27.5 in PBO, improved SF-36
7% stopped due to side effects https://t.co/LJzGzzlgq6 https://t.co/5ybyUdfNjZ
Links:
Dr. John Cush RheumNow ( View Tweet)
RT @Gibson_RheumPAC
Important rheumatology signal: dupilumab-associated inflammatory arthritis. Usually seronegative, imaging-supported, and sometimes persistent despite normal labs. Co-management and careful work-up are essential.#RNL26 https://t.co/r73cSZC59s
Dr. John Cush RheumNow ( View Tweet)
Incretins/GLP-1s are being investigated widely. @RWCSmtg #RWCS26 https://t.co/57JzRJfK8l
Dr. John Cush RheumNow ( View Tweet)
Most inhibition of inflammation is via the brain. More GLP1 and GIP1 receptors are in the brain, more than the gut. @RWCSmtg #RWCS26 https://t.co/CNzUqteBLg
Dr. John Cush RheumNow ( View Tweet)
The hx and timeline of GLP1a development. @RWCSmtg #RWCS26 https://t.co/7tPgcRy4Ze
Dr. John Cush RheumNow ( View Tweet)
Dr. Willa Tsueh taking on hx of GLP-1 agonists. The first ones, Victoza and Tulicity go back to 2010. @RWCSmtg #RWCS26 https://t.co/cKiDCM5xw6
Dr. John Cush RheumNow ( View Tweet)
#RNL26
Haque @HopkinsRheum
1/2 of Americans will be obese by 2030
"Obesity is common & obesity is expensive"
Adipose tissue - active endocrine organ -> cytokines, chemokines, adipokines
Leads to inflamm axis - risk factor similar to 🚬, higher activity, worse response https://t.co/yQLTpE7reY
Dr. John Cush RheumNow ( View Tweet)
RT @ericdeinMD
#RNL26
Dx Modification of OA
@Tuhina_Neogi
Challenge in drug develop:
Models in young animal, not like human OA
Trial enrollment in pts w late, establ OA- not early interv tx
Many paths to OA - target mechanism to correct pt
Slow progress of dx, $$
Endpt? Sx or
Dr. John Cush RheumNow ( View Tweet)
Vasculitis
Sunday’s vasculitis session at RNL26 was a fantastic update on inflamed blood vessels, large and small, by two experts in the field.
https://t.co/ueg3yJDMu4 https://t.co/8uiI9A5G8x
Links:
Dr. John Cush RheumNow ( View Tweet)
RT @Gibson_RheumPAC
GLP-1 receptor agonists do more than promote weight loss.
They impact insulin resistance, inflammation, cardiovascular risk—and may influence musculoskeletal disease. #RNL26 https://t.co/ypKnOJojAm
Dr. John Cush RheumNow ( View Tweet)
RT @Gibson_RheumPAC
Obesity doesn’t just increase risk of rheumatic diseases-it worsens outcomes.
Patients with obesity have higher disease activity, poorer biologic response, and 20–25% lower remission rates in inflammatory arthritis. #RNL26
Dr. John Cush RheumNow ( View Tweet)
Staying Ahead of Spondyloarthritis
The diagnosis and treatment of spondyloarthritis can present challenging clinical scenarios for rheumatologists. At RheumNow Live, Pod IV focused on "Staying Ahead of Spondyloarthritis."
https://t.co/hZeqYC7wi3 https://t.co/2eKEueAukY
Dr. John Cush RheumNow ( View Tweet)
